To include your compound in the COVID-19 Resource Center, submit it here.

Avastin bevacizumab regulatory update

Genentech reiterated its request to maintain accelerated approval for Avastin bevacizumab in combination with paclitaxel for HER2-negative metastatic breast cancer while the company conducts a

Read the full 259 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE